Precancerous lesions in the kidney

Area of Science:

• Urologic Oncology
• Nephrology
• Cancer Research

Background:

• Renal cell carcinoma (RCC) is the most malignant urologic disease, with over 35% mortality.
• Premalignant lesions in the kidney are poorly understood compared to other genitourinary cancers.
• Intratubular epithelial dysplasia is recognized as the primary precursor to RCC.

Purpose of the Study:

• To investigate the nature and significance of premalignant lesions in renal cell carcinoma (RCC).
• To review current understanding of RCC classification, etiology, and genetic alterations.
• To discuss implications for diagnosis, treatment, and follow-up strategies for RCC.

Main Methods:

• Review of histological classifications of RCC, including conventional, papillary, chromophobe, and collecting duct carcinoma.
• Analysis of documented precursor lesions, such as intratubular epithelial dysplasia and von Hippel-Lindau (VHL) syndrome-associated lesions.
• Examination of genetic alterations associated with different RCC subtypes.
• Discussion of established and potential risk factors for RCC development.
• Evaluation of current treatment strategies and their limitations regarding premalignant disease.

Main Results:

• Premalignant lesions like high/low-grade renal intratubular neoplasia are analogous to prostatic intraepithelial neoplasia (PIN).
• Specific genetic alterations characterize different RCC subtypes (e.g., 3p deletion in conventional RCC, trisomies in papillary RCC).
• Risk factors include familial/genetic factors (VHL, hereditary papillary RCC), smoking, obesity, hypertension, and occupational exposures.
• While partial nephrectomy has low recurrence rates (<1%), premalignant lesions may exist.
• Patients with identified premalignant lesions (Renal Intraepithelial Neoplasia - RIN) require closer follow-up.

Conclusions:

• Understanding premalignant lesions is vital for advancing RCC research and patient management.
• While current treatment strategies are largely unaffected by premalignant disease, closer surveillance is recommended for identified cases.
• Further research is needed to identify avoidable risks, develop chemoprevention, and improve early detection in at-risk populations.